NCT02047474 2026-03-06
Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
Yale University
Phase 2 Completed
Clinical Trials
20 trialsNCT02890355 2026-03-05
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03184870 2025-10-09
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02896907 2025-04-30
Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
Thomas Jefferson University
Phase EARLY_PHASE1 Completed
NCT03535727 2024-12-31
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT05546411 2024-12-17
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01905150 2024-12-11
Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer
Bruckner Oncology
Phase 2 Completed
NCT01897454 2023-12-05
Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer
Albert Einstein College of Medicine
Phase 2 Terminated
NCT01726582 2023-08-14
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Medical College of Wisconsin
Phase 2 Completed
NCT00042939 2023-07-06
Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02620865 2023-05-15
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Completed
NCT01926197 2022-10-28
Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer
Stanford University
Phase 3 Completed
NCT03099265 2022-10-27
Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
Yale University
Phase 2 Terminated
NCT01560949 2020-08-10
Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01803282 2020-06-02
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors
Gilead Sciences
Phase 1 Completed
NCT00276744 2018-10-24
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT02345460 2018-07-13
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT01688336 2017-10-06
FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT00871169 2016-06-14
Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
New Mexico Cancer Research Alliance
Phase 2 Completed
NCT01296763 2016-03-22
Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed